<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="39148">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02596750</url>
  </required_header>
  <id_info>
    <org_study_id>252160</org_study_id>
    <nct_id>NCT02596750</nct_id>
  </id_info>
  <brief_title>The Effect of Microneedle Pretreatment on Topical Anesthesia</brief_title>
  <official_title>The Effect of Microneedle Pretreatment on Topical Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the role of microneedle pretreatment in the speed at which anesthesia
      develops after application of topical 4% lidocaine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study evaluates whether the time to anesthesia with topical 4% lidocaine can be
      accelerated with the use of microneedle pretreatment. The study will evaluate the anesthesia
      as a randomized split-body study where each subject serves as their own control. The study
      will be performed on the volar forearm. Prior to application of the topical 4% lidocaine,
      one arm will be exposed to a microneedle pretreatment on a microneedle roller and the other
      arm will be exposed to sham microneedle treatment that will consist of a flat roller with no
      microneedles. Then pain will be assessed with the use of a spring loaded needle lancet that
      will be applied at 2 min, 5 min, 10 min, and 30 minutes after treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analog Scale Pain to Pain Stimulus</measure>
    <time_frame>30 min</time_frame>
    <description>Visual analog Scale pain grading in response to spring loaded needle lancet pain stimulus</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale Pain to Microneedle Pretreatment</measure>
    <time_frame>Pretreatment</time_frame>
    <description>Visual analog pain grading in response to microneedle and sham microneedle pretreatments to the ventral forearms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale Pain to Pain Stimulus</measure>
    <time_frame>2 min</time_frame>
    <description>Visual analog Scale pain grading in response to spring loaded needle lancet pain stimulus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale Pain to Pain Stimulus</measure>
    <time_frame>5 min</time_frame>
    <description>Visual analog Scale pain grading in response to spring loaded needle lancet pain stimulus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale Pain to Pain Stimulus</measure>
    <time_frame>10 min</time_frame>
    <description>Visual analog Scale pain grading in response to spring loaded needle lancet pain stimulus</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Microneedle Pretreatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One ventral forearm is randomized to receive pretreatment with microneedle rollers that are 200 micrometers in length (Clinical Resolution Laboratories, Inc.). Then topical 4% lidocaine is applied and pain in assessed after a pain stimulus at the 2 min, 4 min, 10 min, and 30 min time points.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Microneedle Pretreatment</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>One ventral forearm is randomized to receive pretreatment with sham microneedle rollers (flat roller without any microneedles) that are 200 micrometers in length (Clinical Resolution Laboratories, Inc.). Then topical 4% lidocaine is applied and pain in assessed after a pain stimulus at the 2 min, 4 min, 10 min, and 30 min time points.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Microneedle Roller</intervention_name>
    <description>200 micrometer length microneedles (MR2 roller, Clinical Resolution Laboratories, Inc.) mounted on a disposable roller</description>
    <arm_group_label>Microneedle Pretreatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham microneedle Roller</intervention_name>
    <description>Flat roller without microneedles</description>
    <arm_group_label>Sham Microneedle Pretreatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical 4% lidocaine</intervention_name>
    <arm_group_label>Microneedle Pretreatment</arm_group_label>
    <arm_group_label>Sham Microneedle Pretreatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers

        Exclusion Criteria:

          -  Allergy to lidocaine

          -  Smokers
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raja K Sivamani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC Davis</affiliation>
  </overall_official>
  <reference>
    <citation>Sivamani RK, Stoeber B, Wu GC, Zhai H, Liepmann D, Maibach H. Clinical microneedle injection of methyl nicotinate: stratum corneum penetration. Skin Res Technol. 2005 May;11(2):152-6.</citation>
    <PMID>15807814</PMID>
  </reference>
  <reference>
    <citation>Sivamani RK, Liepmann D, Maibach HI. Microneedles and transdermal applications. Expert Opin Drug Deliv. 2007 Jan;4(1):19-25. Review.</citation>
    <PMID>17184159</PMID>
  </reference>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 3, 2015</lastchanged_date>
  <firstreceived_date>October 31, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Davis</investigator_affiliation>
    <investigator_full_name>Raja Sivamani, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Clinical Dermatology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
